The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Kα inhibitor alpelisib in HER2+ PIK3CA-mutated metastatic breast cancer.
 
Chelsea D. Gawryletz
Research Funding - Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Colleen Dougherty-Gray
No Relationships to Disclose
 
Farrah Mikhail Datko
No Relationships to Disclose
 
Michelle Marie Loch
Research Funding - Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Marina Sharifi
No Relationships to Disclose
 
Ragisha Gopalakrishnan
Research Funding - Conquer Cancer Foundation; Novartis Institutes for BioMedical Research (Inst); Novartis Institutes for BioMedical Research (Inst); Pfizer Hellas (Inst); Seagen (Inst)
 
Peter Kabos
Research Funding - Angiochem (Inst); AstraZeneca (Inst); Genentech (Inst); Lilly (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Signatures in cell-free DNA to detect disease, track treatment response and inform treatment decisions. (Inst)
 
Virginia F. Borges
Stock and Other Ownership Interests - Perla THerapeutics
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Seagen
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Olema Oncology (Inst); Seagen (Inst)
 
Elena Shagisultanova
Research Funding - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)